SMAD4, SMAD family member 4, 4089

N. diseases: 575; N. variants: 144
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.100 GeneticVariation disease BEFREE Patients with gastric juvenile polyposis and SMAD4 mutations are at a high risk of developing gastric cancer; hence, early gastrectomy should be considered. 30873576 2019
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.100 Biomarker disease BEFREE Smad4/Fascin index is highly prognostic in patients with diffuse type EBV-associated gastric cancer. 29572117 2018
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.100 Biomarker disease BEFREE The miR-324-3p/Smad4/Wnt signaling axis may be a potential therapeutic target to prevent GC progression. 29103082 2018
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.100 GeneticVariation disease BEFREE The frequency of genomic alterations seen in SBA demonstrated distinct differences in comparison with either colorectal cancer (APC: 26.8% [85 of 317] vs 75.9% [4823 of 6353], P < .001; and CDKN2A: 14.5% [46 of 317] vs 2.6% [165 of 6353], P < .001) or gastric carcinoma (KRAS: 53.6% [170 of 317] vs 14.2% [126 of 889], P < .001; APC: 26.8% [85 of 317] vs 7.8% [69 of 889], P < .001; and SMAD4: 17.4% [55 of 317] vs 5.2% [46 of 889], P < .001). 28617917 2017
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.100 Biomarker disease BEFREE Collectively, these data demonstrate that miR‑196a‑5p has a key role in EMT and invasion by targeting Smad4 in GCSCs. miR‑196a‑5p may serve as a potential target for gastric cancer therapy. 28440445 2017
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.100 AlteredExpression disease BEFREE Therefore, these findings demonstrate that miR-558 facilitates the progression of gastric cancer through directly targeting the HPSE promoter to attenuate Smad4-mediated repression of HPSE expression. 27685626 2016
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.100 Biomarker disease BEFREE In conclusion, EBV-encoded BARF1 promotes cell proliferation in stomach cancer by upregulating NFκB and miR-146a and downregulating SMAD4, thereby contributing to EBV-induced stomach cancer progression. 27438138 2016
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.100 Biomarker disease BEFREE SB mutagenesis has, thus, helped to catalog the cooperative molecular mechanisms driving SMAD4-induced GC growth and discover genes with potential clinical importance in human GC. 27006499 2016
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.100 AlteredExpression disease BEFREE SGPP2 and Smad4 at mRNA and protein levels were negatively correlated with miR-31 in human GC tissues and cancer cell lines. 26494556 2015
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.100 Biomarker disease BEFREE Increased miR-146a in gastric cancer directly targets SMAD4 and is involved in modulating cell proliferation and apoptosis. 22020746 2012
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.100 Biomarker disease BEFREE In conclusion, our functional screening uncovers multiple miRNAs that regulate the cellular responsiveness to TGF-β signalling and reveals important roles of miR-199a in gastric cancer by directly targeting Smad4. 22821565 2012
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.100 GeneticVariation disease BEFREE These results suggest that genetic variants in the SMAD4 gene play a protective role in gastric cancer in a Chinese population. 21105199 2010
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.100 Biomarker disease BEFREE Thus, this study provides a mechanism by which a balance between Smad4 and Smad7 in human gastric cancer is critical for differentiation, metastasis, and apoptosis of tumor cells. 19341727 2009
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.100 GeneticVariation disease BEFREE SMAD4 mutation carriers had a significantly higher frequency of gastric polyposis (73%) than did patients with BMPR1A mutations (8%) (p<0.001); all seven cases of gastric cancer occurred in families with SMAD4 mutations. 17873119 2007
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.100 AlteredExpression disease BEFREE The rate of reduced Smad4 expression was higher in advanced gastric cancer than early gastric cancer. 15736060 2005
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.100 AlteredExpression disease BEFREE To clarify the clinical significance of TSG expression in gastric carcinoma, the expression of various TSG candidates (p53, E-cadherin, FHIT, smad4, rb, VHL, PTEN, MGMT, p16, and KAI1), as well as other proteins (bcl-2, MUC1, MUC2, MUC5AC, MUC6, CEA, CD44, beta-catenin, C-erbB2, and cyclin B2), was evaluated immunohistochemically in 329 consecutive gastric carcinomas using the tissue array method. 12692839 2003
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.100 GeneticVariation disease BEFREE Allelic loss was also noted on chromosome 18q at a marker near Smad4 in this mutated gastric cancer, apparently producing complete inactivation of Smad4 in this tumor. 9331080 1997
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.100 PosttranslationalModification disease BEFREE Analysis of the DPC4 gene in gastric carcinoma. 9197522 1997